Citius Oncology, Inc (CTOR): חובות להיוון בספרים

This chart of the market valuation of Citius Oncology, Inc. (CTOR) demonstrates the specifics of a biotech developer with negative cash flow and no revenue, where the indicator stands at 0.24. Citius Oncology, Inc. (CTOR) holds unique rights to LYMPHIR for the therapy of rare lymphomas. However, the business's success depends on US regulatory approval and subsequent reimbursement by insurance companies.

This ratio determines the degree of capital structure dependence on borrowed funds by comparing total liabilities to the book value of equity. By analyzing the total debt-to-book capitalization chart, an investor assesses the financial stability of Citius Oncology, Inc. (CTOR), which is supported by the stability of the US domestic market and the humanitarian status of oncology developments, minimizing the impact of external geopolitical shocks.